Eli Lilly’s Zepbound Found to Have Additional Clinical Benefits in New Study

A cohort study recently published in JAMA Network Open has found that Eli Lilly’s blockbuster antidiabetic drug Zepbound (tirzepatide) is linked to lower risks of major complications compared to GLP-1 receptor agonist (RA) drugs, suggesting additional clinical boons for the highly sought medication.
Source: Drug Industry Daily